Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Olaparib in Recurrent Ovarian Cancer
NCT02489006Phase 2Active, not recruiting
- Sponsor
- University Health Network
- Start
- Jul 2016
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of olaparib in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by University Health Network. Started Jul 2016; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT02489006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02489006.